Compass Therapeutics (CMPX) Price & Analysis

Compare

370 Followers

CMPX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.18 - $4.08

Previous CloseN/A

Volume16.21M

Average Volume (3M)1.21M

Market Cap

$466.68M

Enterprise Value$268.49M

Total Cash (Recent Filing)$100.95M

Total Debt (Recent Filing)$9.90M

Price to Earnings (P/E)―

Beta2.21

Next Earnings

Nov 06, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding171,572,500

10 Day Avg. Volume1,963,940

30 Day Avg. Volume1,211,121

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-731.58

Enterprise Value/Ebitda-4.03

Forecast

1Y Price Target

$12.67

Price Target Upside319.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe trial achieved statistical significance in the primary endpoint of overall response rate, showing better results for tovecimig + paclitaxel compared to paclitaxel alone.

Market PotentialThe landscape in 2L BTC is barren, with room for a new standard of care to obtain meaningful market share in the majority of patients without available targeted therapy.

Product DevelopmentThe company made significant progress in advancing its lead asset, tovecimig, a bispecific DLL4/VEGF-A antibody.

Bears Say

Financial ProjectionsThe company reported cash and cash equivalents of $101mn, which the company expects to provide runway into 2027, not inclusive of costs to build a commercial infrastructure for tovecimig.

Market ValuationThe valuation is predicated on a ~3x EV/5-year forward sales estimate, which is a premium to the small cap peer group trading at ~1x.

Operational ConcernsManagement confirmed the trial is proceeding smoothly without any operational issues that could explain the slow event accrual rate.

Compass Therapeutics News

Compass Therapeutics 33.3M share Spot Secondary priced at $3.00

Jefferies, Piper Sandler and Guggenheim acted as joint book running managers for the offering. Published first on TheFly...

11d ago

CMPX

Compass Therapeutics announces common stock offering, no amount given

Compass Therapeutics (CMPX) announced the launch of an underwritten public offering of its common stock and, in lieu...

11d ago

CMPX

Compass Therapeutics price target raised to $12 from $10 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Compass Therapeutics (CMPX) to $12 from $10 and...

12d ago

CMPX

Compass Therapeutics reports Q2 EPS (14c), consensus (12c)

“Following our previous announcement that the tovecimig Phase 2/3 trial met the primary endpoint of overall response rate,...

13d ago

CMPX

Compass Therapeutics announces anticipated cash runway into 2027

As of June 30, 2025, cash and marketable securities were $101 million as compared to $127 million as...

13d ago

CMPX

Compass Therapeutics Announces Public Offering to Raise $112.5M

An update from Compass Therapeutics ( ($CMPX) ) is now available. On August 12, 2025, Compass Therapeutics announced...

10d ago

CMPX

Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions

Compass Therapeutics, Inc. (CMPX) has disclosed a new risk, in the Economy & Political Environment category. Compass Therapeutics,...

12d ago

CMPX

Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress

Compass Therapeutics, Inc. ( ($CMPX) ) has released its Q2 earnings. Here is a breakdown of the information...

12d ago

CMPX

Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, with...

12d ago

CMPX

Compass Therapeutics Reports Promising Q2 2025 Results

An announcement from Compass Therapeutics ( ($CMPX) ) is now available. Compass Therapeutics reported its second quarter 2025...

13d ago

CMPX

Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Drive Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CMPX stock, giving a Buy rating yesterday....

2M ago

CMPX

Promising Outlook for Compass Therapeutics: Buy Rating Backed by Tovecimig’s Potential and Strategic Positioning

Sean McCutcheon, an analyst from Raymond James, has initiated a new Buy rating on Compass Therapeutics (CMPX). Sean...

2M ago

CMPX

Compass Therapeutics resumed with an Outperform at Raymond James

Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics (CMPX) with an Outperform rating and $9 price...

2M ago

CMPX

Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer

Compass Therapeutics, Inc. (($CMPX)) announced an update on their ongoing clinical study. Compass Therapeutics, Inc. (CMPX) recently completed...

2M ago

CMPX

CMPX FAQ

What was Compass Therapeutics’s price range in the past 12 months?

Compass Therapeutics lowest stock price was $1.18 and its highest was $4.08 in the past 12 months.

What is Compass Therapeutics’s market cap?

Compass Therapeutics’s market cap is $466.68M.

When is Compass Therapeutics’s upcoming earnings report date?

Compass Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 74 days.

How were Compass Therapeutics’s earnings last quarter?

Compass Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.016.

Is Compass Therapeutics overvalued?

According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compass Therapeutics pay dividends?

Compass Therapeutics does not currently pay dividends.

What is Compass Therapeutics’s EPS estimate?

Compass Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Compass Therapeutics have?

Compass Therapeutics has 171,572,500 shares outstanding.

What happened to Compass Therapeutics’s price movement after its last earnings report?

Compass Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 23.704%.

Which hedge fund is a major shareholder of Compass Therapeutics?

Currently, no hedge funds are holding shares in CMPX

Compass Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.84%

Trailing 12-Months

Asset Growth

-25.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics (CMPX) Earnings & Revenues

Historic Earnings Reports

CMPX Earnings Call

Q2 2025

0:00 / 0:00

CMPX Stock 12 Month Forecast

Average Price Target

$12.67

▲(319.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.95,4.569230769230769,6.188461538461539,7.8076923076923075,9.426923076923078,11.046153846153846,12.665384615384614,14.284615384615385,15.903846153846153,17.523076923076925,19.142307692307693,20.76153846153846,22.38076923076923,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.95,3.697692307692308,4.445384615384615,5.193076923076923,5.940769230769231,6.688461538461539,7.436153846153846,8.183846153846154,8.931538461538462,9.67923076923077,10.426923076923078,11.174615384615386,11.92230769230769,{"y":12.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.95,3.2615384615384615,3.5730769230769233,3.884615384615385,4.196153846153846,4.507692307692308,4.819230769230769,5.130769230769231,5.4423076923076925,5.753846153846154,6.065384615384616,6.376923076923077,6.688461538461539,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >